Bardoxolone Methyl

甲基巴多索隆

Report date: 2026/01/08 20:00:10
NME

Base Information

Drug NameBardoxolone Methyl
Drug Alias Name巴多索隆Bard - Reata Pharmaceuticals巴多索龙bardoxolonebardoxolonum +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInhibitor of NF-kappa-B kinase (IKK) inhibitorsNuclear factor NF-kappa-B complex inhibitors
TargetsNuclear factor NF-kappa-B complexInhibitor of NF-kappa-B kinase (IKK)
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursDiabetes Mellitus, Type 2 +[23] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[18] 
CombinationsNo
Global Highest StatusDiscontinued (NDA/BLA)
Highest Status in ChinaN/A
Originator CompaniesKyowa Hakko Kirin Co LtdReata Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKyowa Kirin Co LtdReata Pharmaceuticals IncBiogen Inc +[4] 
Active IndicationsN/A
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Solid tumoursDiabetes Mellitus, Type 2 +[23] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG